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Abstract
 
Viral protein R (Vpr), an apoptogenic accessory protein encoded by HIV-1, induces mito-
chondrial membrane permeabilization (MMP) via a specific interaction with the permeability
transition pore complex, which comprises the voltage-dependent anion channel (VDAC) in
the outer membrane (OM) and the adenine nucleotide translocator (ANT) in the inner mem-
brane. Here, we demonstrate that a synthetic Vpr-derived peptide (Vpr52-96) specifically binds
to the intermembrane face of the ANT with an affinity in the nanomolar range. Taking advan-
tage of this specific interaction, we determined the role of ANT in the control of MMP. In
planar lipid bilayers, Vpr52-96 and purified ANT cooperatively form large conductance chan-
nels. This cooperative channel formation relies on a direct protein–protein interaction since it
is abolished by the addition of a peptide corresponding to the Vpr binding site of ANT. When
added to isolated mitochondria, Vpr52-96 uncouples the respiratory chain and induces a rapid
inner MMP to protons and NADH. This inner MMP precedes outer MMP to cytochrome 
 
c
 
.
Vpr52-96–induced matrix swelling and inner MMP both are prevented by preincubation of
purified mitochondria with recombinant Bcl-2 protein. In contrast to König’s polyanion
(PA10), a specific inhibitor of the VDAC, Bcl-2 fails to prevent Vpr52-96 from crossing the
mitochondrial OM. Rather, Bcl-2 reduces the ANT–Vpr interaction, as determined by affinity
purification and plasmon resonance studies. Concomitantly, Bcl-2 suppresses channel forma-
tion by the ANT–Vpr complex in synthetic membranes. In conclusion, both Vpr and Bcl-2
modulate MMP through a direct interaction with ANT.
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Molecular Mechanisms of Mitochondrial Membrane Permeabilization
 
Introduction
 
Mitochondrial membrane permeabilization (MMP)
 
1
 
 is a
key event of apoptotic cell death associated with the release
of caspase activators and caspase-independent death effec-
tors from the intermembrane space, dissipation of the inner
mitochondrial
 
 
 
transmembrane potential (
 
DC
 
m
 
), and a per-
turbation of oxidative phosphorylation (1–7). Pro- and an-
tiapoptotic members of the Bcl-2 family regulate inner and
outer MMP through interactions with the adenine nucle-
otide translocator (ANT) in the inner membrane (IM), the
voltage-dependent anion channel (VDAC) in the outer
membrane (OM), and/or through autonomous channel-
forming activities (5–10). ANT and VDAC are major com-
ponents of the permeability transition pore complex
(PTPC), a polyprotein structure organized at sites at which
the two mitochondrial membranes are apposed (7, 11). It is
a matter of debate whether Bcl-2 primarily regulates MMP
through its interaction with VDAC or ANT.
The HIV-1 viral protein of regulation, viral protein R
(Vpr), is abundant in virions (12–14) and is detectable in
the serum of HIV-1 carriers, correlating with the viral load
(15). Vpr has pleiotropic effects on viral replication and
cellular proliferation, differentiation, cytokine production,
nuclear factor 
 
k
 
B–mediated transcription, and apoptosis
(13, 16–18). In HIV-1–infected cultures, Vpr is found in
the nuclear and membrane fractions as well as the condi-
tioned medium (19). Since Vpr can cross the plasma mem-
brane (20–22), it can gain access to intracellular compart-
ments not only as a consequence of the viral life cycle, but
also independently from the infection process (i.e., via a
“bystander effect”). In addition, Vpr can localize to mito-
chondria to kill cells by apoptosis (20, 22–25). Full-length
(Vpr1-96) or truncated synthetic forms of Vpr act on the
PTPC to induce all mitochondrial hallmarks of apoptosis,
including 
 
DC
 
m
 
 loss and the release of cytochrome 
 
c
 
 and
apoptosis-inducing factor (AIF) (22). The MMP-inducing
activity of Vpr resides in its COOH-terminal moiety
(Vpr52-96), within an 
 
a
 
-
 
helical motif of 12 amino acids
(Vpr71-82) containing several critical arginine (R) residues
(R73, R77, R80) which are strongly conserved among dif-
ferent pathogenic HIV-1 isolates (22–24).
In this study, we used Vpr and Vpr-derived peptides as a
tool to dissect the molecular events of MMP and its control
by Bcl-2. Here we demonstrate that Vpr52-96 physically
and functionally interacts with ANT to form large conduc-
tance channels, closure of VDAC abrogates Vpr52-96
binding to mitochondria, Vpr triggers inner MMP through
its interaction with ANT before outer MMP, and Bcl-2
prevents the Vpr52-96–induced MMP through a direct in-
teraction with ANT.
 
Materials and Methods
 
Plasmon Resonance.
 
NH
 
2
 
-terminally biotinylated peptides
(Vpr52-96, Vpr52-96[R73A,80A], or an irrelevant control pep-
tide, HWWRAESDEARRCYNDPKCCDFVTNR) were im-
mobilized on biosensor chips of a BIAcore™ apparatus (Amer-
sham Pharmacia Biotech), and 140 nM highly purified ANT
from rat heart mitochondria (26) was added (time 0, on) in the
mobile phase (5 
 
m
 
l/min) for real time measurement (in resonance
units, RU). When required, the surface was regenerated using 1 M
NaCl containing 0.05% P20 detergent (BIAcore). The data were
analyzed using the v3.0 software and fitted to a 1:1 Langmuir
binding model with separate 
 
k
 
on
 
 and
 
 k
 
off
 
 determination. The asso-
ciation constant (
 
K
 
A
 
) was determined as 
 
k
 
off
 
/
 
k
 
on
 
, and the dissocia-
tion constant (
 
K
 
D
 
) as 1/
 
K
 
A
 
.
 
 
 
Control experiments revealed no spe-
cific binding of Vpr52-96 to recombinant VDAC (a gift from C.
Mannella, Wadsworth Center, Albany, NY; reference 27), with-
out any difference between Vpr52-96 and Vpr52-96[R73A, 80A]
and without detectable saturation for VDAC concentrations up
to 10 
 
m
 
M.
 
ANT Purification and Reconstitution in Liposomes.
 
ANT was
purified from rat heart mitochondria as described previously (8).
After mechanical shearing, mitochondria were suspended in 220
mM mannitol, 70 mM sucrose, 10 mM Hepes, 200 
 
m
 
M EDTA,
100 mM dithiothreitol, 0.5 mg/ml subtilisin, pH 7.4, kept on ice
for 8 min, and sedimented twice by differential centrifugations (5
min, 500 
 
g
 
; 10 min, 10,000 
 
g
 
). Mitochondrial proteins were solu-
bilized by 6% (vol/vol) Triton X-100 (Boehringer) in 40 mM
K
 
2
 
HPO
 
4
 
, 40 mM KCl, 2 mM EDTA, pH 6.0, for 6 min at room
temperature (RT), and solubilized proteins were recovered by
ultracentrifugation (30 min, 24,000 
 
g
 
, 4
 
8
 
C). Then, 2 ml of this
Triton X-100 extract was applied to a column filled with 1 g of
hydroxyapatite (BioGel HTP; Bio-Rad Laboratories), eluted
with previous buffer, and diluted (vol/vol) with 20 mM MES,
200 
 
m
 
M EDTA, 0.5% Triton X-100, pH 6.0. Subsequently, the
sample was separated with a Hitrap SP column using an FPLC
system (Amersham Pharmacia Biotech) and a linear NaCl gradi-
ent (0–1 M). Protein concentration was determined using micro-
BCA assay (Pierce Chemical Co.). Purified ANT and/or re-
combinant Bcl-2 was reconstituted in phosphatidylcholine (PC)/
cardiolipin liposomes. In brief, to prepare liposomes, 45 mg PC
and 1 mg cardiolipin were mixed in 1 ml of chloroform, and the
solvent was evaporated under nitrogen. Dry lipids were resus-
pended in 1 ml liposome buffer (125 mM sucrose plus 10 mM
Hepes, pH 7.4) containing 0.3% 
 
n
 
-octyl-
 
b
 
-
 
D
 
-pyranoside and
mixed by continuous vortexing for 40 min at RT. ANT (0.1
mg/ml) or recombinant Bcl-2 (0.1 mg/ml) was then mixed with
liposomes (vol/vol) and incubated for 20 min at RT. Proteolipo-
somes were finally dialyzed overnight at 4
 
8
 
C.
 
Vpr Binding to Liposomes.
 
Proteoliposomes or plain lipo-
somes were exposed to different concentrations of FITC-labeled
Vpr52-96 for 30 min in liposome buffer, washed (290,000 
 
g
 
, 45
min, 10
 
8
 
C), and analyzed in a FACS Vantage™ (Becton Dickin-
son) cytofluorometer (X 
 
6 
 
SD,
 
 n 
 
5 
 
3).
 
Pore-opening Assay.
 
ANT proteoliposomes were sonicated in
the presence of 1 mM 4-methylumbelliferylphosphate
 
 (
 
4-MUP)
and 10 mM KCl (50 W, 22 s, sonifier model 250; Branson) on
ice as described previously (28). Then, liposomes were separated
on Sephadex G-25 columns (PD-10; Amersham Pharmacia Bio-
tech) from unencapsulated products. 25-
 
m
 
l aliquots of liposomes
were diluted to 3 ml in 10 mM Hepes, 125 mM saccharose, pH
7.4, mixed with various concentrations of the proapoptotic in-
ducers, and incubated for 1 h at RT. Potential inhibitors of MMP
such as BA, ATP, and ADP were added to the liposomes 30 min
 
1
 
Abbreviations used in this paper:
 
 ANT, adenine nucleotide translocator;
Atr, atractyloside; BA, bongkrekic acid; CCCP, carbonylcyanide 
 
m
 
-chlo-
rophenylhydrazone; CsA, cyclosporin A; 
 
DC
 
m
 
, mitochondrial transmem-
brane potential; FSC, forward scatter; IM, inner membrane; MMP, mito-
chondrial membrane permeabilization; OM, outer membrane; PA10,
König’s polyanion; PC, phosphatidylcholine; PTPC, permeability transi-
tion pore complex; RC, respiratory control; RT, room temperature;
VDAC, voltage-dependent anion channel; Vpr, viral protein R.
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before treatment. After the addition of 10 
 
m
 
l of alkaline phos-
phatase (5 U/ml; Boehringer) diluted in liposome buffer plus 0.5
mM MgCl
 
2
 
, samples were incubated for 15 min at 37
 
8
 
C under
agitation, and the enzymatic conversion of 4-MUP in 4-meth-
ylumbelliferone (4-MU) was stopped by the addition of 150 
 
m
 
l
stop buffer (10 mM Hepes-NaOH, 200 mM EDTA, pH 10).
The 4-MU–dependent fluorescence (360/450 nm) was subse-
quently quantitated (28) using a PerkinElmer spectrofluorimeter.
Atractyloside (Atr), a proapoptotic permeability transition in-
ducer, was used in each experiment as a standard to determine the
100% response. The percentage of 4-MUP release induced by
Vpr-derived peptides was calculated as follows: [(fluorescence of
liposomes treated by Vpr peptide 
 
2
 
 fluorescence of untreated li-
posomes)/(fluorescence of liposomes treated by Atr 
 
2 
 
fluores-
cence of untreated liposomes)] 
 
3 
 
100.
 
Planar Lipid Bilayer Experiments.
 
The pore-forming activities
of ANT, Vpr52-96, Bcl-2, and/or Bax were investigated at the
single channel (patch clamp) levels, following published protocols
(29). Virtually solvent-free planar lipid bilayers were formed by
the method of Montal and Mueller (1972) by the apposition of
two monolayers on a 125-
 
m
 
m-diameter hole in 10-
 
m
 
m thin
Teflon film pretreated with hexadecane/hexane (1:40, vol/vol).
Measurement compartments were glass cells. Membrane currents
under applied voltage were measured using a BLM 120 amplifier
(Biologic) and Ag/AgCl electrodes. The current fluctuations
were stored on a DTR 1202 (Biologic) and transferred to a com-
puter where different measurements (current and histogram am-
plitude) were performed using Satori v3.01 software (Intracel
Ltd.). The lipid mixture palmitoyloleoy-PC/dioleoylphosphati-
dylethanolamine (POPC/DOPE, 7:3, wt/wt) supplemented with
3% cardiolipin (Avanti Polar Lipids, Inc.) was dissolved in 1 or
0.1% hexane, and then was added to both sides of the bilayer in
the macroscopic configuration and to the bath in the “tip-dip”
configuration (2.5 
 
m
 
g protein/ml). Recordings were performed
in symmetric conditions (100 mM KCl, 2 mM MgCl
 
2
 
, 10 mM
Hepes, pH 7.4). Lipid bilayers were preformed at the tip of patch
clamp glass micropipettes by the tip-dip method (30). Bilayer for-
mation was monitored by the capacitance response and, before
protein addition, bare membranes were checked under applied
potentials for electrical silence. Before addition to the bilayer,
proteins were incubated with 1 mM CaCl
 
2
 
, 40 
 
m
 
M Atr, or con-
trol electrolyte (10 mM Hepes, 100 mM KCl, 2 mM MgCl
 
2
 
, pH
7.4) for 30 min at RT, then mixed with evaporated lipid mixture
(60 
 
m
 
g protein/mg lipid) and treated with Biobeads SM-2 (Bio-
Rad Laboratories) to eliminate Triton X-100. In some experi-
ments, Vpr52-96 was added directly to the aqueous subphase af-
ter bilayer formation. Single channel recordings are representative
of the most frequently observed events. ANT was preincubated
or not with Bcl-2 or Bax and added to one compartment, then
Vpr52-96 was added to the same compartment.
 
Binding Assays and Western Blot Analysis.
 
Mouse liver mito-
chondria were isolated as described (22). For the determination of
cytochrome 
 
c
 
 release, supernatants from Vpr52-96–treated mito-
chondria (6,800 
 
g
 
 for 15 min; 20,000 
 
g
 
 for 1 h, both at 4
 
8
 
C) were
frozen at 
 
2
 
80
 
8
 
C until immunodetection of cytochrome 
 
c
 
 (mouse
monoclonal antibody clone 7H8.2C12; BD PharMingen). For
binding assays, purified mitochondria were incubated (250 
 
m
 
g of
protein in 100 
 
m
 
l swelling buffer) for 30 min at RT 5 
 
m
 
M (binding
assay) Vpr52-96 or biotin–Vpr52-96. Mitochondria were lysed ei-
ther after incubation with biotinylated Vpr52-96 or before with
150 
 
m
 
l of a buffer containing 20 mM Tris-HCl, pH 7.6, 400 mM
NaCl, 50 mM KCl, 1 mM EDTA, 0.2 mM PMSF, 100 U/ml
aprotinin, 1% Triton X-100, and 20% glycerol. Such extracts were
 
diluted with 2 vol of PBS plus 1 mM EDTA before the addition of
150 
 
m
 
l avidin-agarose (ImmunoPure; Pierce Chemical Co.) to
capture the biotin-labeled Vpr52-96 complexed with its mito-
chondrial ligand(s) (2 h at 4
 
8
 
C in a roller drum). The avidin-aga-
rose was washed batchwise with PBS (five times with 5 ml; 1,000 
 
g
 
,
5 min, 4
 
8
 
C), resuspended in 100 
 
m
 
l of twofold concentrated
Laemmli buffer containing 4% SDS and 5 mM 
 
b
 
-mercaptoetha-
nol, incubated for 10 min at RT, and centrifuged (1,000 
 
g, 10 min,
48C). Finally, the supernatants were heated at 958C for 5 min and
analyzed by SDS-PAGE (12%), followed by Western blot analysis
and immunodetection with a rabbit polyclonal antiserum against
human ANT (provided by Dr. Heide H. Schmid, The Hormel In-
stitute, University of Minnesota, Austin, MN; reference 31).
Cell Culture and Microinjection Experiments. COS cells (cul-
tured in DMEM Glutamax medium supplemented with Hepes,
antibiotics, and 10% FCS) that were growing on a premarked
V-shaped area of a coverslip (.200 per experiment) were micro-
injected into the cytoplasm using a computer-controlled microin-
jector equipment (Eppendorf; pressure 200 hPa, 0.5 s) with PBS
only, pH 7.2, recombinant human Bcl-2 (amino acids 1–218; 10
mM, purified as described in reference 32), 2 mM König’s polyan-
ion (PA10; a gift of Dieter Brdiczka, University of Konstanz, Kon-
stanz, Germany). After microinjection, cells were cultured in the
absence (Co.) or presence of 1 mM Vpr52-96 for 3 h and stained
for 30 min with 2 mM DCm-sensitive dye 5,59,6,69-tetrachloro-
1,19,3,39-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) (red
fluorescence shows mitochondria with a high DCm, green fluores-
cence shows mitochondria with a low DCm; reference 33).
Flow Cytometric Analysis of Purified Mitochondria. Purified mi-
tochondria were resuspended in PT buffer (200 mM sucrose, 10
mM Tris-MOPS, pH 7.4, 5 mM Tris-succinate, 1 mM Tris-
phosphate, 2 mM rotenone, and 10 mM EGTA). Cytofluoromet-
ric (FACS Vantage™; Becton Dickinson) detection was re-
stricted to mitochondria by gating on the forward scatter (FSC)/
side scatter (SSC) parameters and on the main peak of the FSC-
W parameter. Confirmation a posteriori of the validity of this
double gating was obtained by the labeling of mitochondria with
DCm-insensitive mitochondrial dye MitoTracker® Green (75
nM, green fluorescence; Molecular Probes). To determine the
percentage of mitochondria having a low DCm, the DCm-sensi-
tive fluorochrome JC-1 (200 nM, 570–595 nm) was added 10
min before carbonylcyanide m-chlorophenylhydrazone (CCCP)
or Vpr-derived peptides. The percentage of mitochondria having
a low DCm was determined in dot plot FSC/FL-2 (red fluores-
cence) windows.
Polarographic Studies. Purified mitochondria were incubated
at 378C in a thermostated cell fitted with a Clark electrode (Han-
satech) and containing 250 ml of 0.3 M mannitol, 10 mM KCl, 5
mM MgCl2, 1 mg/ml BSA, and 10 mM KH2PO4, pH 7.4, as de-
scribed (34). Cytochrome c oxidase activities were spectrophoto-
metrically measured (34).
Results
Physical Interaction between Vpr and ANT. Surface plas-
mon resonance measurements indicate that purified deter-
gent-solubilized ANT protein binds to the immobilized
Vpr COOH-terminal moiety biotin–Vpr52-96 (but to a far
lesser extent to mutated biotin–Vpr52-96[R73,80A]) with
an affinity in the nanomolar range (Fig. 1, A and B). This
interaction was modulated by two ANT ligands which
differentially affect ANT conformation (35), namely the
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PTPC activator (opener) Atr, which favored Vpr binding,
and the PTPC inhibitor (closer) bongkrekic acid (BA),
which reduced Vpr binding (Fig. 1 C). Bcl-2–like proteins
bind to a motif of ANT (amino acids 105–155; reference 8)
whose implication in apoptosis control has been confirmed
by deletion mapping (36). This motif partially overlaps
with the second ANT loop (amino acids 92–116), a regula-
tory domain exposed to the intermembrane space (37, 38).
A peptide corresponding to the overlap between the Bcl-2
binding motif and this loop (ANT104-116) inhibited the
ANT–Vpr interaction (Fig. 1 C), presumably via direct as-
sociation with Vpr52-96 (Fig. 1 D). Neither a topologically
related peptide motif derived from the human phosphate
carrier nor mutated and scrambled versions of ANT104-
116 (control peptides in Fig. 1 C) had such inhibitory ef-
fects. Vpr also interacted with ANT incorporated into lipo-
somal membranes. Indeed, Vpr52-96 binding to mem-
branes was greatly facilitated in liposomes in which ANT
has been reconstituted compared with protein-free lipo-
somes (Fig. 2 A). The ANT-facilitated incorporation of
Vpr into membranes was inhibited by BA (Fig. 2 B). In
conclusion, Vpr binds to ANT, at least in part via an inter-
action with a domain of ANT (ANT104-116) that is ex-
posed to the intermembrane side of this protein, coinciding
with the apoptogenic portion of ANT.
Cooperative Channel Formation by Vpr and ANT in Syn-
thetic Membranes. Vpr52-96 (but not the NH2-terminal
moiety of Vpr [Vpr1-51] or mutated Vpr52-96, in which
arginine 77 is replaced by alanine, Vpr52-96[R77A])
caused permeabilization of ANT proteoliposomes (Fig. 2
C), yet had no effect on plain liposomes (data not shown).
ANT104-116 (but not the control peptides) prevented the
Vpr52-96–induced membrane permeabilization of ANT
proteoliposomes (Fig. 2 C), indicating that in the context
of the lipid bilayer, the effect of Vpr involved a direct in-
teraction with ANT. In planar lipid bilayers, low doses of
Vpr52-96 (,1 nM) were incapable of forming channels,
unless ANT was present. ANT and Vpr52-96 cooperated
to form discrete channels whose conductance (190 6 2 pi-
cosiemens [pS]; Fig. 3) was much larger than those formed
by high doses (80 nM) of Vpr52-96 alone (55 6 2 pS) (Fig.
3; reference 39), yet was in the range of those formed by
Ca21-treated ANT (26, 40). These biophysical experiments
demonstrate that ANT and Vpr directly interact in mem-
branes to form functionally competent channel-forming
hetero(poly)mers.
Vpr-induced IM Permeabilization Studied in Isolated Mito-
chondria. Compared with untreated organelles (Fig. 4 A,
trace a), purified mitochondria preincubated with Vpr52-96
(Fig. 4 A, trace b) exhibited a gross deficiency in respiratory
control (RC). Vpr increased succinate oxidation preceding
ADP addition and abolished both the inhibitory effect of
oligomycin (a specific ATPase inhibitor) and the stimula-
tory effect of uncoupling by the protonophore CCCP.
Thus, Vpr52-96 (but not Vpr1-51) reduced the RC (ratio
of oxygen consumption with oligomycin versus CCCP) to
a value of 1.1, compared with 5.3 in control mitochondria
(Table I). The entire Vpr protein (Vpr1-96), and a short
peptide corresponding to the minimum “mitochondri-
otoxic” motif of Vpr (Vpr71-82) (22, 23), also reduced the
RC values (Table I). Noticeably, the Vpr-induced loss of
RC was not associated with a significant decrease of the
oxidation rate (Fig. 4 A), suggesting that no major loss
of membrane-bound cytochrome c occurred on short-
term incubation with Vpr52-96. Accordingly, adding cyto-
chrome c to Vpr52-96–treated mitochondria oxidizing suc-
cinate did not stimulate the rate of oxygen uptake (Fig. 4 A,
trace b). The observation of Vpr-mediated uncoupling of
the respiratory chain prompted us to test its capacity to in-
Figure 1. Physical and functional interaction between Vpr and ANT.
(A) Plasmon surface resonance sensorgrams of the interaction of ANT
with Vpr52-96, Vpr52-96[R73A,80A], or an irrelevant control (Co.).
Only the sensorgram of the interaction with Vpr52-96 exhibits an in-
crease of binding as a function of time and a positive signal at the start of
the dissociation phase (off). The calculated KD (KD5 kon/koff) of the inter-
action is 9.7 6 6.4 nM (X 6 SD, n 5 5). (B) Langmuir isotherm deter-
mined at different concentrations of ANT on sensorgrams corrected
by substraction of the blank (sensorgrams obtained with Vpr52-
96[R73A,80A]). (C) Modulation of the Vpr52-96–ANT interaction by
ANT ligands and ANT-derived peptides. Measurements were performed
as in A, in the absence (u) or presence of BA (250 mM), Atr (50 mM), the
ANT104-116 peptide, or three control peptides (all at 5 mM). ANT-2–
derived peptide ANT104-116 (DKRTQFWRYFAGN) and control
peptides (Co.I: scrambled ANT104-116 [FQNYWGHKRFRDA];
Co.II: mutated ANT104-116 [DGHKQFWGYFAGN]; Co.III: topolog-
ically equivalent peptide [amino acids 149–161]) from the ANT-related
human phosphate carrier protein (SNMLGEENTYLWR). Activation or
inhibition was calculated as (1 2 k0a/k0) 3 100, in which k0a and k0 are
the initial velocity in the presence or absence of the agent, respectively.
(D) Langmuir isotherm for the binding of ANT104-116 to biotinylated
Vpr52-96 (as determined in A). The calculated KD of the interaction is 35
mM. (E) Schematic diagram showing the topology of ANT and the se-
quence of the ANT-2–derived peptide ANT104-116.
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duce IM permeabilization. The IM being essentially imper-
meable to NADH (41), no significant oxygen uptake could
be measured when NADH was added to control mitochon-
dria (Fig. 5 A, trace a). However, addition of Vpr52-96
prompted a significant, NADH-stimulated oxygen con-
sumption (Fig. 5 A, trace b). This indicates that Vpr perme-
abilized the IM both to protons (leading to uncoupling;
Fig. 4 A, trace b) and NADH (Fig. 5 A, trace b). Moreover,
addition of ADP (the physiological substrate of ANT)
strongly inhibited the Vpr-dependent, NADH-stimulated
oxygen consumption (Fig. 5 A, trace c), suggesting that the
ANT–Vpr interaction is essential for inner MMP by Vpr.
Vpr-induced IM Permeabilization Precedes OM Permeabiliza-
tion. To determine the primary site of action of Vpr52-96
on mitochondria, we studied the differential kinetics of in-
ner and outer MMP to NADH and cytochrome c, respec-
tively (Fig. 5 B). NADH oxidation by mitochondria incu-
bated with Vpr52-96 was found maximal 10 min after
addition of Vpr52-96 (Fig. 5 B). Under similar conditions,
Vpr52-96 only induced a marginal access of cytochrome c
to cytochrome c oxidase (Fig. 5 B). Moreover, the DCm
loss occurred before cytochrome c release can be detected
by immunoblot (Fig. 5 C). Hence, Vpr52-96 causes inner
MMP well before OM becomes permeable to cytochrome
c. Accordingly, at the ultrastructural level (see also Fig. 6
C), Vpr52-96–treated mitochondria exhibited matrix swell-
ing before OM rupture became apparent.
Bcl-2 and PA10 Both Prevent MMP Induced by Vpr. Ex-
tracellular addition of Vpr to intact cells induced a rapid
DCm loss before nuclear condensation occurred. This DCm
loss could be fully prevented ($95% of inhibition) by mi-
croinjection of recombinant Bcl-2 into the cytoplasm (Fig.
6 A). Less than 5% of Bcl-2–injected cells manifested a
DCm reduction, whereas 61 6 8% (n 5 3) of vehicle-
microinjected cells exhibited a complete DCm dissipation
in response to Vpr.
Preincubation of purified mitochondria with recombi-
nant Bcl-2 also inhibited the Vpr-mediated inner MMP to
NADH (Fig. 6 B). Concomitantly, Bcl-2 preincubation in-
hibited both the Vpr-induced matrix swelling (Fig. 6 C;
z50% inhibition) and DCm loss (Fig. 6, D and E; z70%
inhibition). No such protective effect was observed when
Bcl-2 was replaced by Bcl-2Da5/6, a deletion mutant lack-
ing the putative pore-forming a5 and a6 helices (42). Two
pharmacological inhibitors of the PTPC (the ANT ligand
BA and the cyclophilin D ligand cyclosporin A [CsA]), as
Figure 2. Physical (A and B) and functional (C) interaction between Vpr and liposomes containing ANT. (A) Dose–response curve of FITC-labeled
Vpr52-96 binding on ANT liposomes and plain liposomes. (B) Binding of FITC–Vpr52-96 (2 mM) to plain liposomes, ANT proteoliposomes, in the
presence or absence of BA (50 mM). (C) Permeabilization of ANT proteoliposomes by Vpr (X 6 SD, n 5 3). Liposomes were loaded with 4-MUP and
exposed for 60 min to Atr (200 mM) or the indicated Vpr-derived peptides (1 mM), in the presence or absence of BA (50 mM), ADP (800 mM), and/or
the indicated peptides (same as in B, 0.5 mM, preincubated with Vpr52-96 for 5 min). Then, alkaline phosphatase was added to convert liposome-
released 4-MUP into the fluorochrome 4-MU, and the percentage of 4-MUP release induced by Vpr-derived peptides was calculated as described in
Materials and Methods.
Figure 3. Electrophysiological properties of Vpr52-96 and ANT in
planar lipid bilayers. Current fluctuations of Vpr52-96 (80 nM, 1150
mV), Vpr52-96 (0.4 nM, 1100 mV), ANT (1 nM, 1110 mV), and
Vpr52-96 plus ANT (0.4:1 nM, 1115 mV), and associated histograms
(right) of conductance levels are shown. (A) Cooperative effect between
ANT and Vpr52-96 at the single channel level. Current fluctuations
of Vpr52-96 (80 nM, 1150 mV), Vpr52-96 (0.4 nM, 1100 mV), ANT
(1 nM, 1110 mV), and Vpr52-96 plus ANT (0.4:1 nM, 1115 mV) after
incorporation into synthetic membranes. Single channel recordings were
performed using the tip-dip technique. The recordings shown are repre-
sentative of at least three independent determinations. (B) Statistical anal-
ysis of conductances obtained in A. Results were expressed as current dis-
tributions at different voltages. Conductances (g; in pS) are calculated by
division of current by voltage.
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well as the specific VDAC inhibitor (closer) PA10 (43), also
inhibited the manifestations of inner MMP (Fig. 6, B–E).
Microinjected PA10 also inhibited the effect of Vpr52-96
on intact cells (Fig. 6 A). In conclusion, both Bcl-2 and
PA10 protect mitochondria against Vpr-induced MMP.
Differential Effects of Bcl-2 and PA10 on Vpr Binding to Mi-
tochondria. When added to purified mitochondria, FITC-
labeled Vpr52-96 rapidly bound to intact mitochondria and
then provoked DCm loss (Fig. 7 A). Binding of Vpr52-96
to purified mitochondria was completely abolished by pre-
incubation of the organelles with PA10, partially reduced
by BA, but not affected by CsA (Fig. 7 B). Thus, Vpr must
access mitochondria through VDAC. Bcl-2 may be ex-
pected to prevent Vpr from crossing the OM via VDAC
(based on the Bcl-2–mediated closure of VDAC; references
9 and 44) and/or to inhibit the Vpr effect on ANT (based
on its physical and functional interaction with ANT; refer-
ences 8, 26, 45). Although recombinant Bcl-2 strongly re-
duced the Vpr52-96–induced matrix swelling (Fig. 6 C)
and DCm loss (Fig. 6, D and E), it failed to impair the bind-
ing of Vpr52-96 to purified mitochondria (Fig. 7 B). The
differential inhibitory effects of PA10 and Bcl-2 on the
Vpr–ANT interaction was confirmed in a distinct experi-
mental system. PA10 fully abolished the affinity-mediated
purification of ANT using biotinylated Vpr52-96 (Fig. 7
C), provided that its effect was assessed on intact mito-
chondria (in which Vpr52-96 has to cross the OM to reach
ANT). In contrast, PA10 did not affect the Vpr52-96–
mediated purification of ANT from Triton-solubilized
mitochondria (in which ANT is readily accessible to
Vpr52-96). In the same conditions, Bcl-2 reduced the
Vpr52-96–mediated recovery of ANT, irrespective of its
addition to intact or solubilized mitochondria (Fig. 7 C).
Thus, Bcl-2 does not interfere with the (PA10-inhibited)
VDAC-mediated conduit, allowing Vpr52-96 to pass the OM.
Bcl-2–mediated Inhibition of the Physical and Functional In-
teraction between Vpr and ANT. A further series of experi-
ments indicated that Bcl-2 modulated the physical and
functional interaction of Vpr with ANT. Recombinant
Bcl-2 (but not Bcl-2Da5/6) reduced Vpr52-96 binding to
soluble (Fig. 8 A) or membrane-associated (Fig. 8 B) ANT.
In an independent series of control experiments, Vpr53-96
was found not to interact with recombinant Bcl-2, as de-
termined by surface plasmon resonance. Hence, inhibition
of the Vpr–ANT binding is likely attributable to a direct
Bcl-2–ANT interaction (8, 26). Accordingly, Bcl-2 abol-
ished the formation of Vpr52-96–induced channels in
ANT-containing lipid bilayers (Fig. 8 C). In contrast, in
the same conditions, Bax exacerbated the conductance of
Vpr52-96–ANT channels to a mean value of 245 6 2 pS
(compared with 190 6 2 pS for Vpr52-96–ANT without
any further addition; Fig. 8 C). In conclusion, Bcl-2 specif-
ically prevents cooperative channel formation by Vpr–
ANT, presumably by disrupting their interaction.
Figure 4. Oxidative properties of purified mitochondria exposed to
Vpr. Oxygen consumption curves after addition of the indicated agents.
Trace a: control mitochondria (no pretreatment). Trace b: mitochondria
pretreated for 10 min with 1 mM Vpr52-96. Numbers along the traces are
nanomoles of O2 consumed per minute per milligram of protein.
Table I. RC Values
Peptide RC
Vpr-51 5.1
Vpr52-96 1.1
Vpr1-96 2.0
Vpr71-82 2.6
None 5.3
RC values were calculated by dividing oxygen consumption in the
presence of CCCP by that measured with oligomycin (determined as in
the legend to Fig. 4), 10 min after the addition of 1 mm Vpr-derived
peptides (mean values of three determinations).
Figure 5. Inner versus outer
MMP. (A) Respirometry per-
formed after addition of NADH
and Vpr52-96 (1 mM). Numbers
along the traces are nmol of O2
consumed per minute per milli-
gram protein. Note that the Vpr-
stimulated, NADH-dependent
O2 consumption was fully sensitive to rotenone. (B) Kinetics of Vpr52-
96–induced IM permeabilization to NADH and OM permeabilization to
reduced cytochrome c. Oxygen consumption was determined in the pres-
ence of 2 mM NADH (j) as in A (trace c) and cytochrome c (15 mM)
oxidation (s) was spectrofluorometrically measured, as described (refer-
ence 34). The 100% value of cytochrome c oxidation was determined by
addition of 2.5 mM laurylmaltoside. (C) Kinetics of Vpr52-96–induced
DCm loss and cytochrome c release. Purified mitochondria were treated
with 1 mM Vpr52-96 subjected to cytofluorometric determination of the
percentage of mitochondria having a low DCm using the DCm-sensitive
fluorochrome JC-1. In parallel, cytochrome c was immunodetected in the
supernatant of mitochondria.
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Discussion
The mechanism by which endogenous end stage effec-
tors achieve permeabilization of the IM and/or OM is a
matter of debate. Depending on the apoptotic stimulus,
permeabilization may affect the OM and IM in a variable
fashion and may or may not be accompanied by matrix
swelling (1, 2, 5–7, 46). In vitro experiments performed on
purified mitochondria or proteins reconstituted into artifi-
cial membranes suggest at least two competing models of
MMP. On the one hand, pore formation by ANT has been
proposed to account for IM permeabilization, osmotic ma-
trix swelling, and consequent OM rupture, resulting be-
Figure 6. Bcl-2–mediated inhibition of
Vpr effects on mitochondria. (A) Vpr52-96–
induced DCm dissipation induced in intact
cells. COS cells were microinjected with 10
mM recombinant human Bcl-2, 2 mM PA10,
or PBS only, then incubated in the absence
(Co.) or presence of 1 mM Vpr52-96 for 3 h,
and stained with 2 mM DCm-sensitive dye
JC-1 (red fluorescence shows mitochondria
with a high DCm, green fluorescence shows
mitochondria with a low DCm). (B) Effect of
Bcl-2 on the Vpr-induced inner MMP to
NADH. Mitochondria were left untreated
(Co.) or were pretreated (10 min) with Bcl-2
(0.8 mM) or BA (10 mM). Oxygen consump-
tion of purified mitochondria was measured
as in the legend to Fig. 5 after addition of
succinate plus CCCP or NADH, as indi-
cated. (C) Ultrastructural effects of Vpr on
isolated mitochondria. Electron micrographs
were obtained after incubation of mitochon-
dria for 5 or 15 min with 3 mM Vpr52-96,
after a 5-min preincubation with 0.8 mM
Bcl-2 or 2 mM PA10. The percentage of
swollen mitochondria was ,5% in the con-
trol, 82 6 4% (n 5 3, X 6 SEM) 5 min after
Vpr addition, 99 6 1% 15 min after Vpr,
52 6 4% after treatment with Bcl-2 plus 15
min Vpr, and 24 6 3% after treatment with
BA plus 15 min Vpr. (D) Effect of Bcl-2 and
PA10 on Vpr52-96–induced DCm dissipation
in purified mitochondria. Isolated mitochon-
dria (200 mg protein/ml) were preincubated
with the indicated inhibitors (5 mM CsA, 50
mM BA, 0.8 mM Bcl-2, 2 mM PA10; 5–10
min), washed (10 min, 6,800 g, 208C), incu-
bated with the DCm-sensitive dye JC-1 (200
nM for 10 min), exposed to 3 mM Vpr52-96
for 5 min, and subjected to flow cytometric
determination of the fluorescence (570–595
nm) and the particle size (FSC). Numbers in-
dicate the percentage of JC-1high and JC-1low
mitochondria among z104 events. (E) Quan-
titation of the frequency of JC-1low mito-
chondria (X 6 SD, n 5 5) after incubation
with different Vpr-derived peptides. Purified
mitochondria were preincubated 10 min with
or without 0.8 mM Bcl-2, 0.8 mM Bcl-
2Da5/6, or 10 mM BA in PT buffer, incu-
bated with the DCm-sensitive dye JC-1 (200
nM for 10 min), and then treated for 5 min
with 3 mM Vpr52-96 (wild-type [wt], bio-
tinylated, or modified as indicated), or 10
min with 5–10 mM Vpr1-96, Vpr1-51,
Vpr71-96, Vpr71-82 (wild-type or modified
as indicated), and finally subjected to flow cy-
tometric analysis as in D.
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cause the surface area of the IM with its folded cristae ex-
ceeds that of the OM. In support of this hypothesis,
proapoptotic molecules such as Bax, Atr, Ca21, and thiol
oxidants cause ANT (which normally is a strictly specific
ADP/ATP antiporter) to form a nonspecific pore (8, 26,
28, 40). On the other hand, VDAC has been suggested to
account for a primary OM permeabilization not affecting
the IM (9, 44). In favor of this hypothesis, the permeabili-
zation of VDAC-containing liposomes to sucrose or cyto-
chrome c is enhanced by Bax and inhibited by Bcl-2 in
vitro (9, 44).
The data presented here indicate that the HIV-1 protein
Vpr52-96 primarily affects IM and not OM permeability in
vitro. Vpr52-96 binds ANT in an ANT conformation–depen-
dent fashion (Fig. 1) and cooperates with it to form
channels (Figs. 2 and 3) which permeabilize the IM before
the OM becomes permeable to cytochrome c (Figs. 4 and
5). Bcl-2 antagonizes this effect (Fig. 6), but clearly does so
independently of VDAC, based on two independent obser-
vations. First, its mode of action clearly differs from that of
the VDAC inhibitor PA10 (Fig. 7). Second, Bcl-2 can af-
fect the physical and functional ANT–Vpr interaction in a
Figure 7. Differential effect of Bcl-2 and PA10 on Vpr52-96 binding
to mitochondria. (A) Vpr52-96 binds mitochondria before inducing DCm
loss. Mitochondria were left unstained (inset in control, top left panel) or
exposed to the DCm-insensitive mitochondrial dye MitoTracker® Green
(75 nM), alone (MTG) or with 0.5 mM FITC–Vpr52-96 (green fluores-
cence) in combination with the DCm-sensitive mitochondrial dye Mi-
toTracker® Red (chloromethyl-X-rosamine; red fluorescence) followed
by cytofluorometric two-color analysis. Numbers indicate the percentage
of mitochondria in each quadrant. (B) PA10, but not Bcl-2, inhibits
Vpr52-96 binding to mitochondria. Mitochondria were preincubated for
10 min with the indicated inhibitors, and the percentage of FITC–Vpr52-
96–labeled mitochondria was determined as in A. (C) Inhibitory effect of
Bcl-2 on affinity purification of ANT by biotinylated Vpr52-96. Mito-
chondria were incubated with the indicated inhibitors, and then exposed
for 30 min at RT with 5 mM biotinylated Vpr52-96. Mitochondria were
lysed either after incubation with biotinylated Vpr52-96 (top) or lysed be-
fore (bottom) with Tris-HCl as described in Materials and Methods. Bio-
tinylated Vpr52-96 complexed with its mitochondrial ligands was re-
tained on avidin-agarose and subjected to immunoblot detection of
ANT. Co, control.
Figure 8. Bcl-2–mediated inhibition of the Vpr–ANT interaction. (A)
Plasmon surface resonance determination of the Bcl-2–mediated inhibi-
tion of interaction between Vpr52-96 and native purified ANT. The in-
teraction was measured after the addition of the indicated concentrations
of recombinant Bcl-2, Bcl-2Da5/6, or recombinant Bid, and data (X 6
SD, n 5 3) were calculated as in the legend to Fig. 1. (B) Effect of Bcl-2
on Vpr binding to ANT proteoliposomes. The retention (X 6 SD, n 5
3) of FITC-labeled Vpr52-96 on ANT proteoliposomes preincubated
with 800 nM Bcl-2 or 2 mM PA10 (followed by washing) was assessed as
in the legend to Fig. 2 A. Co, control. (C) Effect of Bcl-2 on the forma-
tion of Vpr–ANT channels in planar lipid bilayers. Single channel record-
ings (175 mV) of Vpr52-96 plus ANT plus Bax (0.4:1:0.3 nM) and
Vpr52-96 plus ANT plus Bcl-2 (0.4:1:1 nM), and corresponding ampli-
tude histograms are displayed. Control values for Vpr52-96 plus ANT
alone are similar as in Fig. 1 E (data not shown). C, closed; O, open.
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synthetic, VDAC-free system (Fig. 8). It should be noted
that although Bcl-2 is generally considered to be preferen-
tially associated with the mitochondrial OM, some reports
also indicate an IM localization (47–49). This suggests that
Bcl-2 may adopt different submitochondrial localizations
possibly depending on the state of the cell. Although our
data do not exclude the possibility that Bcl-2 modulates the
permeability of VDAC to relatively large, globular proteins
(14.5 kD for cytochrome c, as opposed to the linear, mostly
a helical structure of Vpr52-96 resolved by nuclear mag-
netic resonance; reference 50), they indicate that, at least in
this particular model, Bcl-2 exerts its membrane-protective
mitochondrial effect via ANT.
The fact that PA10-mediated closure of VDAC com-
pletely blocks the binding of Vpr52-96 to intact mitochon-
dria suggests that Vpr52-96 must cross the OM via VDAC
to reach its mitochondrial target(s). Bcl-2 inhibits binding
of Vpr52-96 to ANT in three experimental systems: plas-
mon resonance (Fig. 8 A), ANT proteoliposomes (Fig. 8
B), and affinity purification of ANT by biotinylated Vpr
added to intact or Triton-solubilized mitochondria (Fig. 8
C). Conversely, Vpr52-96 binding to intact mitochondria
was not affected by Bcl-2 (Fig. 7 B). One possible explana-
tion for this result may be that Vpr52-96 has a second mi-
tochondrial target different from ANT. The ANT ligand
BA inhibits the ANT–Vpr52-96 binding (Fig. 1 C) and re-
duces the binding of Vpr to mitochondria to some extent
(Fig. 7 B). One explanation to reconcile the differential in-
hibitory action of Bcl-2 and PA10 is to assume that BA
(but not Bcl-2) affects the Vpr target which is different
from ANT. Alternatively, BA (but not Bcl-2) might mod-
ify the general conformation of the PTPC (including that
of VDAC), and thus reduce the (VDAC-mediated) Vpr
entry into mitochondria.
Irrespective of this latter possibility, our data are compat-
ible with a scenario in which Vpr affects mitochondrial
membrane integrity in four steps (Fig. 9). First, Vpr crosses
the OM via VDAC (inhibition by PA10). Second, the
COOH-terminal half of Vpr (Vpr52-96) interacts with the
ANT104-116 site in ANT (and possibly with other ANT
domains). Third, as a consequence of its association with
Vpr, ANT is converted into a nonspecific pore, leading to
inner MMP. Fourth, inner MMP triggers matrix swelling
resulting in OM rupture.
Recent studies have revealed the existence of several vi-
ral apoptosis inhibitors acting on mitochondria. For exam-
ple, adenovirus, Epstein-Barr virus, herpesvirus saimiri, and
Kaposi sarcoma–associated human herpesvirus 8 produce
apoptosis-suppressive Bcl-2 homologues (51–54). In addi-
tion, several viruses encode PTPC-interacting proteins
without any obvious homology to the Bcl-2/Bax family.
The cytomegalovirus apoptosis inhibitor pUL37X (55) and
Vpr, an HIV-1–encoded apoptosis inducer, selectively bind
to ANT. The proapoptotic p13 (II) protein derived from
the X-II open reading frame of HTLV-1 is also targeted to
mitochondria via a peptide motif that bears structural simi-
larities to the mitochondriotoxic domain of Vpr (56).
Moreover, the proapoptotic, MMP-inducing hepatitis vi-
rus B protein X interacts with VDAC (57). Thus, both
VDAC and ANT emerge as major targets of viral apoptosis
regulation and, perhaps, as targets for pharmacological in-
tervention on viral pathogenesis.
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